CS
CYTK icon

Candriam SCA’s Cytokinetics CYTK Stock Holding History

Candriam SCA’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.7M Buy
443,066
+107,858
+32% +$7.74M 0.17% 125
2026
Q1 		$22.1M Buy
335,208
+188,577
+129% +$12M 0.11% 179
2025
Q4 		$9.32M Buy
+146,631
New +$9.12M 0.05% 280
2025
Q2 		– Sell
-145,191
Closed -$5.84M – 690
2025
Q1 		$5.84M Sell
145,191
-25,369
-15% -$1.17M 0.04% 301
2024
Q4 		$8.02M Sell
170,560
-8,640
-5% -$449K 0.05% 296
2024
Q3 		$9.46M Hold
179,200
– – 0.05% 277
2024
Q2 		$9.71M Sell
179,200
-313,829
-64% -$18.9M 0.06% 255
2024
Q1 		$34.6M Buy
493,029
+225,789
+84% +$17.5M 0.22% 108
2023
Q4 		$22.3M Sell
267,240
-236,000
-47% -$8.55M 0.15% 148
2023
Q3 		$14.8M Sell
503,240
-35,000
-7% -$1.17M 0.11% 181
2023
Q2 		$17.6M Hold
538,240
– – 0.13% 177
2023
Q1 		$17.4M Buy
538,240
+35,000
+7% +$1.43M 0.12% 187
2022
Q4 		$23.1M Hold
503,240
– – 0.16% 153
2022
Q3 		$24.4M Sell
503,240
-17,236
-3% -$830K 0.17% 133
2022
Q2 		$20.4M Sell
520,476
-119,752
-19% -$4.82M 0.17% 139
2022
Q1 		$23.6M Buy
640,228
+126,884
+25% +$4.51M 0.16% 144
2021
Q4 		$23.4M Hold
513,344
– – 0.15% 157
2021
Q3 		$18.3M Hold
513,344
– – 0.12% 188
2021
Q2 		$10.2M Buy
513,344
+137,491
+37% +$3.23M 0.07% 281
2021
Q1 		$7.5M Hold
375,853
– – 0.06% 305
2020
Q4 		$7.81M Buy
375,853
+235,628
+168% +$4.31M 0.06% 313
2020
Q3 		$3.04M Buy
+140,225
New +$3.28M 0.03% 437

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Candriam SCA's CYTK Position: Q2 2026 in Review

Candriam SCA increased its Cytokinetics (CYTK) stake by 32% in Q2 2026, buying an estimated $7.74M and bringing the position to 443,066 shares worth $37.7M. The position accounts for 0.17% of the portfolio, ranked #125.

Candriam SCA first reported a position in CYTK in Q3 2020 and has held it in 22 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Candriam SCA held 443,066 shares of Cytokinetics worth $37.7M as of Q2 2026.
  • Candriam SCA bought 107,858 Cytokinetics shares in Q2 2026, an estimated $7.74M.
  • Cytokinetics made up 0.17% of Candriam SCA's portfolio in Q2 2026, its #125 holding.
  • Candriam SCA first reported a position in Cytokinetics in Q3 2020 and has held it in 22 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.